SCTV01C vaccine

a bivalent recombinant trimeric spike (S) protein vaccine against SARS-CoV-2 variants and its boosters

Also Known As:

SCTV01C; SCTV01C COVID-19 vaccine; SCTV01E; SCTV01E-1; SCTV01E-1 COVID-19 vaccine

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Bell Palsy (Bell's Palsy) 10/01/2023 - "No SAE was reported and one grade 1 AESI (Bell's palsy) was observed in SCTV01C group. "
2.	Infections 01/01/2023 - "Together, our comprehensive immunogenicity evaluation results indicate that SCTV01E could become an important COVID-19 vaccine platform to combat surging infections caused by the highly immune evasive BA.4/5 variants. "
3.	Breakthrough Infections 11/22/2023 - "Encouragingly, the SCTV01E booster consistently induces higher neutralizing titers against all these variants than breakthrough infection does. " 11/22/2023 - "We evaluate the serum neutralization activities of participants who received COVID-19 inactivated vaccine (CoronaVac), those who received the recently approved tetravalent protein vaccine (SCTV01E), or those who had contracted a breakthrough infection with BA.5/BF.7/XBB virus. "
4.	COVID-19 11/22/2023 - "We evaluate the serum neutralization activities of participants who received COVID-19 inactivated vaccine (CoronaVac), those who received the recently approved tetravalent protein vaccine (SCTV01E), or those who had contracted a breakthrough infection with BA.5/BF.7/XBB virus. "